Fig. 1.
Fig. 1. RFS in AML patients in morphologic CR depending on the number of leukemic cells in BM aspirate, assessed by immunophenotype, after induction treatment. The two groups of patients are as follows: (A) ≥5 × 10−3 leukemic cells (n = 18), with a median survival of 17 months; and (B) less than 5 × 10−3 leukemic cells (n = 24), in which the median survival has not been reached.

RFS in AML patients in morphologic CR depending on the number of leukemic cells in BM aspirate, assessed by immunophenotype, after induction treatment. The two groups of patients are as follows: (A) ≥5 × 10−3 leukemic cells (n = 18), with a median survival of 17 months; and (B) less than 5 × 10−3 leukemic cells (n = 24), in which the median survival has not been reached.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal